Education ▼

SPECIALTY TOPICS

CURRENTLY VIEWING
Chronic Lymphocytic Leukemia

Breast Cancer

Gastrointestinal Cancer

Colorectal Cancer

Ovarian Cancer

Prostate Cancer

Precision Medicine in Oncology^®

Neoadjuvant HER2+

More >>

Chronic Lymphocytic Leukemia

Acalabrutinib Shows Benefit in Ibrutinib-Treated Relapsed/Refractory CLL

$Acalabrutinib Shows Benefit in Ibrutinib-Treated Relapsed/Refractory CLL$

Kerry A. Rogers, MD, highlights the findings of a study examining acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia and the next steps for the data.
Read More >>

FDA Grants Acalabrutinib Breakthrough Designation for CLL

Ibrutinib EU Indications Expanded in CLL and Waldenstrom Macroglobulinemia

FDA Approves Rituximab Biosimilar for CD20+ B-Cell Non-Hodgkin Lymphoma and CLL

Preclinical Research Suggests Role for ITK Inhibition in Monocytic MDSCs in CLL

BTK Inhibitors Show Continued Promise in CLL

View More Stories >>

View Conference Coverage

Charlotte Plasma Cell Disorder Congress

State of the Science Summit on Breast Cancer in Long Island

2019 International Lung Cancer Congress

2019 State of the Science Summit on Genitourinary Cancers in Jacksonville

2019 State of the Science Summit on Hematologic Malignancies in Pittsburgh

Dr. Shadman on the Efficacy of Venetoclax in CLL

Dr. Abedin on PI3K Inhibitors in CLL

Dr. Sharman on the Potential Future of Acalabrutinib in CLL

OncLive houses thousands of videos that provide updates and information.
See more Videos

CLL: Practical Advice on Selecting and Managing Therapy

Acalabrutinib's Role in Treating Chronic Lymphocytic Leukemia

Venetoclax + Obinutuzumab: Impact on CLL Management

Frontline Therapy in CLL: Combination Strategies and MRD

Stratifying Patients With CLL to Frontline Therapy

Ibrutinib's Role as Frontline Therapy in CLL

OncLive houses thousands of videos that provide updates and information.
See more Videos

BTK Inhibitors in Chronic Lymphocytic Leukemia

Genomic Profiling in Chronic Lymphocytic Leukemia

Venetoclax-Based Regimens as First-Line Therapy in CLL

$Relapsed/Refractory CLL: Evaluating Other Novel Agents$

$Novel Approaches to Treating Relapsed/Refractory CLL$

$Continuing Therapy in Relapsed/Refractory CLL$

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

Other Promising Strategies in CLL

This expert panel discussion led by William Wierda, MD, focuses on promising strategies available for the treatment of chronic lymphocytic leukemia. Dr. Wierda is joined in this discussion by Steven Coutre, MD; Matthew S. Davids, MD, MMSc; Nicole Lamanna, MD; and Shuo Ma, MD, PhD.

View Now

The Use of Novel PI3K Inhibitors in CLL

In this segment William Wierda, MD, PhD, leads a panel discussion regarding the use of novel PI3K inhibitors in chronic lymphocytic leukemia.

View Now

Featured Video

Dr. Richardson Discusses New Directions in Multiple Myeloma

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, discusses new directions in multiple myeloma. View now

Priority Review Designation in GIST, Promising Findings in Bladder Cancer and NSCLC, and More